抗氨甲酰化蛋白抗体在类风湿关节炎中与间质性肺病相关
该横断面研究纳入179例符合2010 ACR/EULAR标准的类风湿关节炎(RA)患者,其中37例(21%)诊断为RA相关间质性肺病(RA-ILD)。抗氨甲酰化蛋白抗体(Anti-CarP)各特异性在RA-ILD患者中更常见且滴度更高,多变量分析显示其显著增加ILD风险,复制样本结果一致。
要点
- Anti-CarP各特异性在RA-ILD患者中阳性率更高(如Anti-FCS 70% vs 43%)。
- 多变量分析中Anti-FCS、Anti-CFFHP和Anti-FCS-IgA显著增加ILD风险。
- 复制样本中观察到相似关联,支持Anti-CarP与RA-ILD的关联。
核心结论
- Anti-CarP与类风湿关节炎患者的间质性肺病(ILD)强烈相关。
- 高瓜氨酸化在RA-ILD中的作用值得进一步研究。
研究设计与样本
- 横断面研究纳入符合2010 ACR/EULAR标准的RA患者,主队列分RA-ILD组与非ILD RA组,疑似ILD者经诊断流程确认后转入RA-ILD组。
- ILD由高分辨率计算机断层扫描诊断并经多学科委员会确认,另设独立复制样本。
- 通过自制ELISA检测三种Anti-CarP IgG(抗FCS、抗Fib、抗CFFHP)和一种Anti-CarP IgA(抗FCS-IgA)。
主要发现
- 共纳入179例患者,37例(21%)最终诊断为RA-ILD。
- Anti-CarP各特异性在RA-ILD患者中更频繁:Anti-FCS 70% vs 43%;Anti-Fib 73% vs 51%;Anti-CFFHP 38% vs 19%;Anti-CarP-IgA 51% vs 20%,所有比较p<0.05。
- RA-ILD患者血清Anti-CarP滴度显著更高。
- 多变量分析中Anti-CarP各特异性增加ILD的比值比:Anti-FCS(OR: 3.42;95% CI: 1.13 to 10.40)、Anti-Fib(OR: 2.85;95% CI: 0.83 to 9.70)、Anti-CFFHP(OR: 3.11;95% CI: 1.06 to 9.14)、Anti-FCS-IgA(OR: 4.30;95% CI: 1.41 to 13.04)。
- 复制样本中观察到相似发现。
关键数值与推荐
- RA诊断符合2010 ACR/EULAR标准。
- ILD诊断由高分辨率计算机断层扫描确认并经多学科委员会核实。
- 多变量逻辑回归调整吸烟、性别、年龄、RA病程、类风湿因子和抗瓜氨酸化蛋白抗体。
临床怎么用
- 在RA患者中检测Anti-CarP各特异性可能有助于识别ILD高风险患者。
- 对Anti-CarP阳性RA患者应关注ILD的筛查与监测。
局限性
- 横断面设计不能确定因果关系。
- 样本量有限,部分OR的95%置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyse the association between anti-carbamylated protein antibodies (Anti-CarP) and interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients. METHODS: Cross-sectional study including RA patients fulfilling the 2010 ACR/EULAR criteria. The main population comprised two groups: (1) RA patients diagnosed with RA-ILD (RA-ILD group); (2) RA patients without ILD (non-ILD RA group). Non-ILD RA patients in whom ILD was suspected underwent a diagnostic work-up and, if ILD was diagnosed, were switched to the RA-ILD group. ILD was diagnosed by high-resolution computed tomography and confirmed by a multidisciplinary committee. An independent replication sample was also obtained. Three Anti-CarP IgG autoantibodies against fetal calf serum (Anti-FCS), fibrinogen (Anti-Fib) and chimeric fibrine/filagrine homocitrullinated peptide (Anti-CFFHP) and one Anti-CarP IgA against FCS (Anti-FCS-IgA) were determined by home-made ELISA. Associations between Anti-CarP and ILD were analysed using multivariable logistic regression adjusted by smoking, sex, age, RA disease duration, rheumatoid factor and anticitrullinated protein antibodies. RESULTS: We enrolled 179 patients: 37 (21%) were finally diagnosed with RA-ILD. Anti-CarP specificities were more frequent in RA-ILD patients (Anti-FCS 70% vs 43%; Anti-Fib 73% vs 51%; Anti-CFFHP 38% vs 19%; Anti-CarP-IgA 51% vs 20%, p<0.05 for all comparisons). Serum titers of Anti-CarP were significantly higher in RA-ILD patients. Anti-CarP specificities showed a robust effect towards increasing the odds of ILD in the multivariate analysis (Anti-FCS (OR: 3.42; 95% CI: 1.13 to 10.40), Anti-Fib (OR: 2.85; 95% CI: 0.83 to 9.70), Anti-CFFHP (OR: 3.11; 95% CI: 1.06 to 9.14) and Anti-FCS-IgA (OR: 4.30; 95% CI: 1.41 to 13.04)). Similar findings were observed in the replication sample. CONCLUSIONS: Anti-CarP were strongly associated with ILD. The role of homocitrullination in RA-ILD merits further investigation.
引用
- Castellanos-Moreira R, Rodríguez-García SC, Gomara MJ, et al. Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. Ann Rheum Dis. 2020. PMID: 32156708. doi:10.1136/annrheumdis-2019-216709
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。